Congress Materials

Medical Information
Gulf Countries
 

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
SelectI am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
I am a patient / caregiverNo, go back to the patient portal
SelectI am a patient / caregiverNo, go back to the patient portal
I am a Healthcare Professional in another country.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Kristian Reich, Jonathan I. Silverberg, Marjolein de Bruin-Weller, Mette Deleuran, Lisa A. Beck, Kim Papp, Saleem A. Farooqui, Fan Zhang, Claire Feeney, Herwig Koppensteiner March 21, 2023 AAD 2023 Atopic Dermatitis

Abrocitinib Long-Term Efficacy for up to 96 Weeks in Patients With Moderate‑to‑Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study

View Presentation
Poster
Jacob P. Thyssen, Jonathan I. Silverberg, Gil Yosipovitch, Shawn G. Kwatra, Jose-Manuel Carrascosa, Patrick M. Brunner, Irina Lazariciu, Claire Feeney, Francisco J. Rebollo, Herwig Koppensteiner March 21, 2023 AAD 2023 Atopic Dermatitis

Efficacy and Safety of Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis in the Presence or Absence of Comorbid Asthma or Allergic Rhinitis: A Post Hoc Pooled Analysis of JADE COMPARE and JADE DARE

View Presentation
Poster
Jonathan I. Silverberg, Robert S. Kirsner, David Margolis, Michael Tharp, Daniela E. Myers, Karen Annis, Daniela Graham, Chuanbo Zang, Bonnie L. Vlahos, Paul Sanders March 21, 2023 AAD 2023 Stasis Dermatitis

Efficacy and Safety of Crisaborole Ointment, 2%, in Participants Aged ≥45 Years With Stasis Dermatitis: Results From a Phase 2a Fully Decentralized Proof-of-Concept Study

View Presentation
Poster
Melinda Gooderham, Eric Simpson, Bob Geng, Linda F. Stein Gold, Andreas Wollenberg, Saleem A. Farooqui, Fan Zhang, Claire Feeney, Melissa Watkins, Herwig Koppensteiner March 21, 2023 AAD 2023 Atopic Dermatitis

Influence of Baseline Disease Severity Defined by Investigator’s Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate‑to‑Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study

View Presentation
Oral Presentation
Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, Kevin Winthrop, Emma Guttman-Yassky, Alexander Egeberg, Haiyun Fan, Justine Alderfer, Susan Johnson, Saleem Farooqui March 21, 2023 AAD 2023 Atopic Dermatitis

Integrated Safety Analysis of Abrocitinib in 3802 Patients With Moderate-To-Severe Atopic Dermatitis With Over 5000 Patient-Years of Exposure

View Presentation
Poster
Jennifer Soung, Brett King, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rie Ueki, Rodney Sinclair, Fan Zhang, Helen Tran, Robert Wolk March 21, 2023 AAD 2023 Alopecia

Integrated safety analysis of ritlecitinib in adolescent patients with alopecia areata from the randomized, placebo-controlled ALLEGRO phase 2b/3 and ongoing open-label phase 3 ALLEGRO-LT studies

View Presentation
Poster
Jonathan I. Silverberg, Kristian Reich, Marjolein de Bruin-Weller, Mette Deleuran, Lisa A. Beck, Kim Papp, Saleem A. Farooqui, Fan Zhang, Claire Feeney, Melissa Watkins March 21, 2023 AAD 2023 Atopic Dermatitis

Response to Abrocitinib up to Week 96 According to Short-Term Response: A Post Hoc Analysis of the JADE-EXTEND Phase 3 Trial

View Presentation
Poster
Maryanne Senna, Seth Forman, Lindsey Bordone, Pablo De La Cueva Dobao, Robert Wolk, Samuel H. Zwillich, Fan Zhang, Haytham Mohamed Ahmed, Liza Takiya March 21, 2023 AAD 2023 Alopecia

Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study

View Presentation
Oral Presentation
Melissa Piliang, Charles Lynde, Brett King, Paradi Mirmirani, Rodney Sinclair, Robert Wolk, Samuel H. Zwillich, Helen Tran, Fan Zhang, Liza Takiya March 21, 2023 AAD 2023 Alopecia

Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study

View Presentation
Oral Presentation
Ruth Ann Vleugels, Aaron R Mangold, Victoria P Werth, Lisa Christopher-Stine, Alisa Femia, Myron Chu, Natalie Rath, Abigail Sloan, Mikhail Salganik, Christopher Banfield, David Fiorentino March 21, 2023 AAD 2023 Dermatomyositis

The Efficacy, Safety, and Tolerability of PF-06823859, an Interferon-β Specific Monoclonal Antibody, in Adult Patients with Dermatomyositis: Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study

View Presentation